Mesoblast Reports Strong Q1 Sales for Ryoncil®
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2026
0mins
Should l Buy MESO?
Source: seekingalpha
- Strong Sales Performance: Mesoblast reported gross sales of $35.3 million and net revenues of $30.3 million for Q1, with robust sales in February and March offsetting January's holiday seasonality, indicating improved market acceptance of Ryoncil®.
- Near $100 Million Annual Revenue: Revenue generated during the first year of Ryoncil® launch approaches $100 million, demonstrating the product's rapid growth potential in the market, which could solidify the company's future financial performance.
- Optimized Cash Flow Management: The net operating cash spend for the quarter was $4.1 million, primarily driven by receipts of $34.6 million and tight control over operating expenses, showcasing the company's effectiveness in financial management.
- Strong Cash Reserves: As of March 31, 2026, Mesoblast had $122 million in cash reserves, providing ample funding for future R&D and market expansion, thereby enhancing investor confidence in the company's long-term growth prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MESO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MESO
Wall Street analysts forecast MESO stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 14.800
Low
35.00
Averages
35.00
High
35.00
Current: 14.800
Low
35.00
Averages
35.00
High
35.00
About MESO
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mesoblast Reports Strong Q1 Sales for Ryoncil®
- Strong Sales Performance: Mesoblast reported gross sales of $35.3 million and net revenues of $30.3 million for Q1, with robust sales in February and March offsetting January's holiday seasonality, indicating improved market acceptance of Ryoncil®.
- Near $100 Million Annual Revenue: Revenue generated during the first year of Ryoncil® launch approaches $100 million, demonstrating the product's rapid growth potential in the market, which could solidify the company's future financial performance.
- Optimized Cash Flow Management: The net operating cash spend for the quarter was $4.1 million, primarily driven by receipts of $34.6 million and tight control over operating expenses, showcasing the company's effectiveness in financial management.
- Strong Cash Reserves: As of March 31, 2026, Mesoblast had $122 million in cash reserves, providing ample funding for future R&D and market expansion, thereby enhancing investor confidence in the company's long-term growth prospects.
See More
Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial
- Ryoncil® Sales Surge: Ryoncil® achieved gross sales of $35.3 million and net revenues of $30.3 million in Q3 FY2026, indicating total revenues nearing $100 million since its launch last year, reflecting strong market demand and product acceptance.
- Optimized Cash Flow Management: The net operating cash spend for the quarter was $4.1 million, significantly reduced due to $34.6 million in receipts and tight control of operating expenses, enhancing the company's financial stability.
- Clinical Trial Progress: Mesoblast successfully met its patient recruitment target in the pivotal Phase 3 trial for the second-generation product rexlemestrocel-L for chronic low back pain, laying the groundwork for future product launches and potentially solidifying the company's market leadership in this area.
- Acquisition and Innovation: The company acquired a patented chimeric antigen receptor (CAR) technology platform aimed at enhancing the potency of therapeutic mesenchymal stem cell products, which is expected to provide more effective treatments for ulcerative colitis and Crohn's disease, further solidifying Mesoblast's innovative leadership in cell therapy.
See More
Mesoblast Achieves Patient Recruitment Target in Chronic Low Back Pain Trial
- Financial Highlights: In the quarter ending March 31, 2026, Mesoblast reported Ryoncil® gross sales of $35.3 million and net revenues of $30.3 million, indicating a strong market performance with total revenues approaching $100 million since last year's launch, showcasing significant growth potential.
- Trial Success: The company successfully achieved its patient recruitment target in the pivotal Phase 3 trial for chronic low back pain, which not only lays the groundwork for subsequent clinical trials but also accelerates the potential market entry of new therapies, enhancing competitive positioning in this therapeutic area.
- Technology Acquisition: Mesoblast acquired an exclusive global license for genetically modified technology aimed at enhancing the precision of cell therapy products, a strategic move that is expected to strengthen its market position in treating inflammatory diseases and potentially yield higher therapeutic efficacy.
- R&D Day Event: During the inaugural R&D day on April 8, Mesoblast highlighted its label extension strategy for Ryoncil® in adult and pediatric rare diseases, emphasizing its leadership in cell therapy innovation, which is anticipated to drive future revenue growth.
See More
Mesoblast Announces RYONCIL® Net Revenues of $30.3 Million and Reduced Net Operating Cash Expenditure of $4.1 Million for the Quarter
- Revenue Report: The company reported revenues of US$30.3 million for the quarter.
- Operating Cash Spend: There was an improved net operating cash spend of US$4.1 million for the same period.
See More
Mesoblast Completes Patient Recruitment for Chronic Low Back Pain Trial
- Trial Recruitment Completed: Mesoblast Limited has successfully completed patient recruitment for its pivotal Phase 3 trial targeting chronic low back pain, enrolling at least 300 patients, which marks a significant step towards a non-opioid treatment option for millions of affected individuals.
- Trial Design and Objectives: Participants will be randomly assigned to receive either a single injection of rexlemestrocel-L or a sham control, with the primary endpoint focusing on pain reduction at the one-year mark, while secondary endpoints will assess improvements in function, quality of life, and reductions in pain medication usage.
- Therapy Background and Potential: Rexlemestrocel-L is an allogeneic stromal cell product designed to target inflammation in degenerating discs, and earlier Phase 3 results indicated meaningful reductions in pain and opioid use, with the therapy holding RMAT designation from the U.S. FDA, allowing for priority review upon Biologics License Application submission.
- Market Demand and Outlook: Chronic low back pain affects over 7 million people in the U.S. and accounts for nearly half of prescription opioid use, highlighting the strong demand for safer, long-term treatment alternatives, with Mesoblast's CEO emphasizing that this milestone supports the company's goal of delivering a disease-modifying, non-opioid option.
See More
Mesoblast Completes Patient Recruitment for Chronic Low Back Pain Trial
- Trial Recruitment Achieved: Mesoblast announced that its pivotal Phase 3 clinical trial for chronic low back pain has successfully recruited 300 patients, marking a significant milestone in its commercialization plans for rexlemestrocel-L, which is expected to enhance the company's market share in this treatment area.
- FDA Approved Design: The trial is a randomized, placebo-controlled study aimed at confirming the efficacy of rexlemestrocel-L in reducing chronic low back pain, with top-line results anticipated in mid-2027, and positive outcomes will support a regulatory filing with the FDA in Q3 CY2027.
- Significant Market Potential: Chronic low back pain affects over 7 million people in the U.S., with Mesoblast projecting potential peak year revenues exceeding $10 billion, highlighting a substantial commercial opportunity in the non-opioid treatment market.
- Clear Strategic Goals: CEO Silviu Itescu emphasized that the success of this trial will drive the company's goal of delivering a non-opioid, disease-modifying therapy, addressing the significant unmet medical needs of chronic low back pain patients.
See More
Mesoblast Reports Strong Q1 Sales for Ryoncil®
- Strong Sales Performance: Mesoblast reported gross sales of $35.3 million and net revenues of $30.3 million for Q1, with robust sales in February and March offsetting January's holiday seasonality, indicating improved market acceptance of Ryoncil®.
- Near $100 Million Annual Revenue: Revenue generated during the first year of Ryoncil® launch approaches $100 million, demonstrating the product's rapid growth potential in the market, which could solidify the company's future financial performance.
- Optimized Cash Flow Management: The net operating cash spend for the quarter was $4.1 million, primarily driven by receipts of $34.6 million and tight control over operating expenses, showcasing the company's effectiveness in financial management.
- Strong Cash Reserves: As of March 31, 2026, Mesoblast had $122 million in cash reserves, providing ample funding for future R&D and market expansion, thereby enhancing investor confidence in the company's long-term growth prospects.
See More
Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial
- Ryoncil® Sales Surge: Ryoncil® achieved gross sales of $35.3 million and net revenues of $30.3 million in Q3 FY2026, indicating total revenues nearing $100 million since its launch last year, reflecting strong market demand and product acceptance.
- Optimized Cash Flow Management: The net operating cash spend for the quarter was $4.1 million, significantly reduced due to $34.6 million in receipts and tight control of operating expenses, enhancing the company's financial stability.
- Clinical Trial Progress: Mesoblast successfully met its patient recruitment target in the pivotal Phase 3 trial for the second-generation product rexlemestrocel-L for chronic low back pain, laying the groundwork for future product launches and potentially solidifying the company's market leadership in this area.
- Acquisition and Innovation: The company acquired a patented chimeric antigen receptor (CAR) technology platform aimed at enhancing the potency of therapeutic mesenchymal stem cell products, which is expected to provide more effective treatments for ulcerative colitis and Crohn's disease, further solidifying Mesoblast's innovative leadership in cell therapy.
See More
Mesoblast Achieves Patient Recruitment Target in Chronic Low Back Pain Trial
- Financial Highlights: In the quarter ending March 31, 2026, Mesoblast reported Ryoncil® gross sales of $35.3 million and net revenues of $30.3 million, indicating a strong market performance with total revenues approaching $100 million since last year's launch, showcasing significant growth potential.
- Trial Success: The company successfully achieved its patient recruitment target in the pivotal Phase 3 trial for chronic low back pain, which not only lays the groundwork for subsequent clinical trials but also accelerates the potential market entry of new therapies, enhancing competitive positioning in this therapeutic area.
- Technology Acquisition: Mesoblast acquired an exclusive global license for genetically modified technology aimed at enhancing the precision of cell therapy products, a strategic move that is expected to strengthen its market position in treating inflammatory diseases and potentially yield higher therapeutic efficacy.
- R&D Day Event: During the inaugural R&D day on April 8, Mesoblast highlighted its label extension strategy for Ryoncil® in adult and pediatric rare diseases, emphasizing its leadership in cell therapy innovation, which is anticipated to drive future revenue growth.
See More
Mesoblast Announces RYONCIL® Net Revenues of $30.3 Million and Reduced Net Operating Cash Expenditure of $4.1 Million for the Quarter
- Revenue Report: The company reported revenues of US$30.3 million for the quarter.
- Operating Cash Spend: There was an improved net operating cash spend of US$4.1 million for the same period.
See More
Mesoblast Completes Patient Recruitment for Chronic Low Back Pain Trial
- Trial Recruitment Completed: Mesoblast Limited has successfully completed patient recruitment for its pivotal Phase 3 trial targeting chronic low back pain, enrolling at least 300 patients, which marks a significant step towards a non-opioid treatment option for millions of affected individuals.
- Trial Design and Objectives: Participants will be randomly assigned to receive either a single injection of rexlemestrocel-L or a sham control, with the primary endpoint focusing on pain reduction at the one-year mark, while secondary endpoints will assess improvements in function, quality of life, and reductions in pain medication usage.
- Therapy Background and Potential: Rexlemestrocel-L is an allogeneic stromal cell product designed to target inflammation in degenerating discs, and earlier Phase 3 results indicated meaningful reductions in pain and opioid use, with the therapy holding RMAT designation from the U.S. FDA, allowing for priority review upon Biologics License Application submission.
- Market Demand and Outlook: Chronic low back pain affects over 7 million people in the U.S. and accounts for nearly half of prescription opioid use, highlighting the strong demand for safer, long-term treatment alternatives, with Mesoblast's CEO emphasizing that this milestone supports the company's goal of delivering a disease-modifying, non-opioid option.
See More
Mesoblast Completes Patient Recruitment for Chronic Low Back Pain Trial
- Trial Recruitment Achieved: Mesoblast announced that its pivotal Phase 3 clinical trial for chronic low back pain has successfully recruited 300 patients, marking a significant milestone in its commercialization plans for rexlemestrocel-L, which is expected to enhance the company's market share in this treatment area.
- FDA Approved Design: The trial is a randomized, placebo-controlled study aimed at confirming the efficacy of rexlemestrocel-L in reducing chronic low back pain, with top-line results anticipated in mid-2027, and positive outcomes will support a regulatory filing with the FDA in Q3 CY2027.
- Significant Market Potential: Chronic low back pain affects over 7 million people in the U.S., with Mesoblast projecting potential peak year revenues exceeding $10 billion, highlighting a substantial commercial opportunity in the non-opioid treatment market.
- Clear Strategic Goals: CEO Silviu Itescu emphasized that the success of this trial will drive the company's goal of delivering a non-opioid, disease-modifying therapy, addressing the significant unmet medical needs of chronic low back pain patients.
See More
